GLP-1 agonists may lead to increased nausea and vomiting in the early postoperative period after total hip arthroplasty, ...
MedPage Today on MSN4d
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without DiabetesThe prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...
A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...
The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide treatment." Topline data results from the study were highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback